Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis
Top Cited Papers
Open Access
- 20 March 2019
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 116 (14), 7015-7020
- https://doi.org/10.1073/pnas.1814685116
Abstract
Malaria and cryptosporidiosis, caused by apicomplexan parasites, remain major drivers of global child mortality. New drugs for the treatment of malaria and cryptosporidiosis, in particular, are of high priority; however, there are few chemically validated targets. The natural product cladosporin is active against blood- and liver-stage Plasmodium falciparum and Cryptosporidium parvum in cell-culture studies. Target deconvolution in P. falciparum has shown that cladosporin inhibits lysyl-tRNA synthetase (PfKRS1). Here, we report the identification of a series of selective inhibitors of apicomplexan KRSs. Following a biochemical screen, a small-molecule hit was identified and then optimized by using a structure-based approach, supported by structures of both PfKRS1 and C. parvum KRS (CpKRS). In vivo proof of concept was established in an SCID mouse model of malaria, after oral administration (ED90 = 1.5 mg/kg, once a day for 4 d). Furthermore, we successfully identified an opportunity for pathogen hopping based on the structural homology between PfKRS1 and CpKRS. This series of compounds inhibit CpKRS and C. parvum and Cryptosporidium hominis in culture, and our lead compound shows oral efficacy in two cryptosporidiosis mouse models. X-ray crystallography and molecular dynamics simulations have provided a model to rationalize the selectivity of our compounds for PfKRS1 and CpKRS vs. (human) HsKRS. Our work validates apicomplexan KRSs as promising targets for the development of drugs for malaria and cryptosporidiosis.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1032548)
- Wellcome (094090)
- Wellcome (105021)
- Wellcome (100993/Z/13/Z)
- Medicines for Malaria Venture (NA)
- Medicines for Malaria Venture (RD/08/2800)
- HHS | National Institutes of Health (R21AI123690)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201200025C)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201700059C)
This publication has 33 references indexed in Scilit:
- Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite CladosporinCell Host & Microbe, 2012
- Asymmetric Total Synthesis of Cladosporin and IsocladosporinThe Journal of Organic Chemistry, 2012
- P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-ActionPLOS ONE, 2012
- Thousands of chemical starting points for antimalarial lead identificationNature, 2010
- A genomic glimpse of aminoacyl-tRNA synthetases in malaria parasite Plasmodium falciparumBMC Genomics, 2009
- High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trialBMC Infectious Diseases, 2009
- Improved Murine Model of Malaria UsingPlasmodium falciparumCompetent Strains and Non-Myelodepleted NOD-scid IL2RγnullMice Engrafted with Human ErythrocytesAntimicrobial Agents and Chemotherapy, 2009
- Bioluminescent assays for ADMETExpert Opinion on Drug Metabolism & Toxicology, 2007
- Structure of the unusual seryl-tRNA synthetase reveals a distinct zinc-dependent mode of substrate recognitionThe EMBO Journal, 2006
- A succession of substrate induced conformational changes ensures the amino acid specificity of Thermus thermophilus prolyl-tRNA synthetase: comparison with histidyl-tRNA synthetaseJournal of Molecular Biology, 2001